PHILADELPHIA, PA — Quotient Sciences announced an expanded commercial supply partnership with Ipsen to manufacture Sohonos (palovarotene), a treatment for Fibrodysplasia Ossificans Progressiva, an ultra-rare disease affecting fewer than 1,000 people worldwide.
The therapy was approved by the U.S. Food and Drug Administration in 2023.
Under the agreement, Ipsen has invested in new equipment at Quotient Sciences’ Boothwyn, Pennsylvania manufacturing facility to support production of the treatment.
The equipment includes a pneumatic closed transfer system designed to safely move materials during production and a flexible dispensing isolator intended to improve operator safety during manufacturing.
Quotient Sciences said the additions expand the facility’s ability to handle highly potent active pharmaceutical ingredients used in specialized drug manufacturing.
Marlene Leuenberger, vice president and general manager of Quotient Sciences in Philadelphia, said the investment supports the company’s work in producing treatments for rare diseases.
“This significant investment in advanced containment and manufacturing technology at our Boothwyn facility underscores Quotient Sciences’ commitment to supporting patients with ultra-rare diseases,” Leuenberger said.
The partnership is intended to maintain commercial supply of Sohonos and expand manufacturing capabilities for highly potent compounds, the company said.